...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biological chemistry >Developments in anticancer vaccination: budding new adjuvants
【24h】

Developments in anticancer vaccination: budding new adjuvants

机译：抗癌疫苗接种的发展：萌芽新佐剂

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The immune system has a limited capacity to recognize and fight cells that become cancerous and in cancer patients, the immune system has to seek the right balance between cancer rejection and host-immunosupression. The tumor milieu builds a protective shell and tumor cells rapidly accumulate mutations that promote antigen variability and immune-escape. Therapeutic vaccination of cancer is a promising strategy the success of which depends on a powerful activation of the cells of the adaptive immune system specific for tumor-cell detection and killing (e.g. CD4+ and CD8+ T-cells). In the last decades, the search for novel adjuvants that enhance dendritic cell (DC) function and their ability to prime T-cells has flourished and some Toll-like receptor (TLR) agonists have long been known to be valid immune adjuvants. The implementation of TLR-synthetic agonists in clinical studies of cancer vaccination is replacing the initial use of microbial-derived products with some encouraging results. The purpose of this review is to summarize the latest discoveries of TLR-synthetic agonists with adjuvant potential in anti-cancer vaccination.
机译：免疫系统能够识别和对抗癌症患者癌症和癌症患者的细胞的能力有限，免疫系统必须寻求癌症排斥和宿主免疫抑制之间的良好平衡。肿瘤Milieu构建保护壳和肿瘤细胞快速积累促进抗原变异性和免疫逸出的突变。癌症的治疗疫苗是一个有前途的策略，其成功取决于特异于肿瘤细胞检测和杀灭的适应性免疫系统细胞的强大激活（例如CD4 +和CD8 + T细胞）。在过去的几十年中，寻找增强树突细胞（DC）功能的新佐剂和它们的素T细胞的能力已经繁荣，并且已经已知一些可收费的受体（TLR）激动剂是有效的免疫佐剂。在癌症疫苗接种临床研究中实施TLR合成激动剂正在替代微生物衍生产品的初始使用，并令一些令人鼓舞的结果。本综述的目的是总结TLR合成激动剂的最新发现具有抗癌疫苗接种的佐剂潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号